Pediatric cancers predominantly constitute lymphomas and leukemias. Recently, our knowledge and awareness about genetic diversities, and their consequences in these diseases, have greatly expanded. Modern solutions are focused on mobilizing and impacting a patient’s immune system. Strategies to stimulate the immune system, to prime an antitumor response, are of intense interest. Amid those types of therapies are chimeric antigen receptor T (CAR-T) cells, bispecific antibodies, and antibody–drug conjugates (ADC), which have already been approved in the treatment of acute lymphoblastic leukemia (ALL)/acute myeloid leukemia (AML). In addition, immune checkpoint inhibitors (ICIs), the pattern recognition receptors (PRRs), i.e., NOD-like receptors (NLRs), Toll-like receptors (TLRs), and several kinds of therapy antibodies are well on their way to showing significant benefits for patients with these diseases. This review summarizes the current knowledge of modern methods used in selected pediatric malignancies and presents therapies that may hold promise for the future.

Complaints of diarrhea and other gastrointestinal symptoms are common among endurance runners. These problems may interfere with athletic activities and be the main cause of underperformance during sports events. It is estimated that this difficulty affects 30 to 90 percent of long-distance runners. The most important pathophysiological factors affecting the occurrence of gastrointestinal symptoms are ischemia and mechanical damage to the intestines, as well as the secretion of neuroendocrine substances. The diet before physical exercise is also one of the most significant factors related to the appearance of gastrointestinal symptoms. Avoiding the intake of fat, caffeine, protein, fiber, non-steroidal anti-inflammatory drugs and dehydration before performance is one of the suggestions for preventing runner’s diarrhea. There are new recommendations for athletes, such as avoidance of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) and the intake of multiple transportable carbohydrates. It seems that a short-term gluten free diet has no effect on the performance of athletes but further research is needed. Mechanisms of runner’s diarrhea are still poorly understood, so more research needs to be conducted to improve the recommendations to runners.

Introduction and purpose: Bartholin's glands are paired structures, playing a significant role in lubricating the vagina through the production of mucus. They are physiologically undetectable, but when their ducts are clogged, the accumulating secretion can lead to various pathologies. The most common are cysts and abscesses, the symptomatic conditions of which are the causes of nearly 2% of gynecological visits annually. Statistically, they most frequently occur in women of childbearing age, however, young age is not a rule. The aim of the study is to summarize the state of knowledge about Bartholin's gland cysts and abscesses, with an indication of the currently used therapies. State of knowledge: In some cases, the course of these pathologies can be asymptomatic, however, the rest of the patients may experience unpleasant symptoms and require treatment. During diagnostics, it is important to carefully collect an interview and conduct a physical examination, because in most cases on this basis it is possible to make an accurate diagnosis. However, in case of doubt, imaging tests can also be used. There may be times when patients with asymptomatic cysts may not require treatment. Nevertheless, choosing the right therapy is sometimes challenging for the clinician due to the potential risk of symptoms recurring. Conclusion: Although there are many different treatments available, the most commonly used appears to be marsupialization or incision and drainage with Word catheter placement. Additionally, an increasing number of articles devoted to the use of the CO2 laser can also be observed, but even it has its drawbacks. For this reason, there is still a need for further research into new methods of treatment that would ensure both good results and high comfort for the patients.

The use of poly (ADP-ribose) polymerase (PARP) inhibitors has recently increased as a result of demonstrating their superior efficacy compared to traditional chemotherapy in various cancer subtypes in many preclinical studies and clinical trials. A better understanding of the molecular mechanisms of PARP and their underlying foci that can be used as screening markers for potential new therapeutic options would aid rational treatment strategies and improve long-term patient outcomes. The available data on acute leukemia suggest potential windows for effective treatment of PARPi in disease subgroups. In this review, we summarize the current advances in the most common PARP-based adjuvant therapies and combination strategies for the treatment of acute leukemia and discuss the future prospects and challenges of therapy with PARP inhibitors. We also discuss reports describing an increased risk of cancer treatment in patients receiving PARP inhibitors for solid tumors. The research material were publications, the search was carried out using a combination of keywords such as: "PARP inhibitor", "acute leukemia", "therapy", "PARP clinical trials". The first step was to find relevant publications from the last 15 years. The second step was to review the publications found. Studies have shown that PARP inhibitors play an increasing role in the treatment of leukemia. In addition, focusing research efforts on identifying the most effective drug combinations and sequences could help to further shape the role of PARPi in the treatment of acute myeloid leukemia (AML).

Introduction and purpose: Muscle weakness in newborns, infants and young children can be caused by disorders of the neuromuscular junction (NMJ). Congenital myasthenic syndromes (CMS) are a group of rare genetic diseases whose symptoms resemble the clinical picture of autoimmune myasthenia gravis. There are many mutations that can disrupt the neuromuscular transmission leading to pathology. The diagnosis of CMS is based on genetic testing. The aim of this study is to draw clinicians' attention to the symptoms and present current forms of CMS diagnosis and management. State of knowledge: An increasing number of genetic changes are associated with CMS pathology. They are divided, depending on the location in the NMJ of the encoded protein, into presynaptic, synaptic and postsynaptic. The most common disorder is the mutation of CHRNE, which is responsible for the expression of one of the subunits in the structure of the acetylcholine receptor. Regardless of the type of disease, the characteristic symptom is uncommon fatigue of skeletal muscles. It may present as ptosis of one or both eyelids or gait disturbance. The interview, laboratory tests and EMG are helpful in the diagnosis, but genetic tests play a key role. They can target specific mutations or cover the entire genome comprehensively. Currently used drugs alleviate the course of CMS by increasing the release of acetylcholine or increasing the concentration of acetylcholine in the synaptic cleft. Conclusion: Because of its rarity and variability, many CMS patients may be misdiagnosed. It is important to implement extensive genetic diagnostics and early implementation of treatment. There is a need for long-term studies of CMS cases and implementation of therapies targeted at specific mutations.